Posted by Michael Wonder on 27 Nov 2019
Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
26 November 2019 - Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing decisions in the U.S. for multiple sclerosis drugs have been driven by other factors, especially what competitors are doing, according to four executives whose insights were described in a new paper.
Besides competition, the executives also cited overall corporate growth objectives, the ability to set U.S. prices higher than in other countries, and distortions caused by the complicated rebate system used to establish insurance reimbursement, the researchers reported in Neurology.
